We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+2.69%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$8.16B
AUM Growth
+$296M
Cap. Flow
-$1.61B
Cap. Flow %
-19.71%
Top 10 Hldgs %
74.41%
Holding
114
New
7
Increased
22
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$80.1M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$65.5M
3
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$58.8M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$48.9M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$35.8M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$84.5M
2
CHTP
CHELSEA THERAPEUTICS INT'L LTD
CHTP
+$37.3M
3
HALO icon
Halozyme
HALO
+$24.8M
4
GILD icon
Gilead Sciences
GILD
+$23.4M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 39.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GEVA
1
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$1.12B 13.68%
10,660,432
+12,250
+0.1% +$1.04M
PCYC
2
DELISTED
PHARMACYCLICS INC
PCYC
$860M 10.54%
9,591,546
+853,658
+10% +$80.1M
SGEN
3
DELISTED
Seagen Inc. Common Stock
SGEN
$860M 10.53%
22,472,229
+1,732,803
+8% +$65.5M
INCY icon
4
Incyte
INCY
$25.5B
$838M 10.26%
14,845,559
+10,000
+0.1% +$511K
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.43B
$463M 5.67%
20,481,442
– –
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$374M 4.58%
13,654,902
+752
+0% +$20K
ITMN
7
DELISTED
INTERMUNE INC
ITMN
$209M 2.55%
4,722,869
+398,026
+9% +$14.7M
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.43B
$139M 1.7%
10,890,872
+5,023,841
+86% +$48.9M
BMRN icon
9
BioMarin Pharmaceuticals
BMRN
$12B
$119M 1.45%
1,908,230
+25,000
+1% +$1.51M
XOMA
10
DELISTED
Xoma
XOMA
$106M 1.3%
1,153,299
+420
+0% +$36.4K
AVNR
11
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$105M 1.28%
18,558,487
+12,768,348
+221% +$58.8M
VNDA icon
12
Vanda Pharmaceuticals
VNDA
$302M
$70.7M 0.87%
4,372,153
-73,543
-2% -$980K
ANAC
13
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$57.6M 0.71%
3,248,043
+152,725
+5% +$2.46M
DYAX
14
DELISTED
DYAX CORPORATION
DYAX
$54.5M 0.67%
5,681,237
+3,149,471
+124% +$24M
RPRX
15
DELISTED
Repros Therapeutics Inc.
RPRX
$48.1M 0.59%
2,778,654
– –
MRTX
16
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$47.6M 0.58%
2,380,074
– –
QCOR
17
DELISTED
QUESTCOR PHARMA INC
QCOR
$46.2M 0.57%
500,000
-217,745
-30% -$18.6M
CERS icon
18
Cerus
CERS
$577M
$42.5M 0.52%
10,246,591
+1,791,285
+21% +$7.67M
DSCI
19
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$40.9M 0.5%
3,537,137
– –
ARAV
20
DELISTED
Aravive, Inc. Common Stock
ARAV
$34.9M 0.43%
+207,648
New +$35.8M
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
$32.8M 0.4%
793,221
+263,231
+50% +$13.6M
HRTX icon
22
Heron Therapeutics
HRTX
$91.6M
$32.1M 0.39%
2,607,784
+440,000
+20% +$5.26M
ACOR
23
DELISTED
Acorda Therapeutics
ACOR
$30.5M 0.37%
7,551
-782
-9% -$3.19M
HALO icon
24
Halozyme
HALO
$9.88B
$27.4M 0.34%
2,776,143
-2,921,996
-51% -$24.8M
GILD icon
25
Gilead Sciences
GILD
$165B
$21.2M 0.26%
256,108
-300,000
-54% -$23.4M
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2014 Portfolio in Review

As of Q2 2014, Baker Bros. Advisors held 114 positions worth $8.16B, up 3.8% from $7.87B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Baker Bros. Advisors withdrew a net $1.61B in Q2 2014, closing 9 positions and reducing 9 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $84.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 43% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Aravive, Inc. Common Stock worth $34.9M.

  • Baker Bros. Advisors's largest Q2 2014 buy was Aravive, Inc. Common Stock: 207,648 shares worth $34.9M.
  • Baker Bros. Advisors added most to PHARMACYCLICS INC in Q2 2014, an estimated $80.1M increase.
  • Baker Bros. Advisors's biggest Q2 2014 reduction was Halozyme, cutting an estimated $24.8M.
  • Baker Bros. Advisors fully exited Intercept Pharmaceuticals, Inc. in Q2 2014, selling an estimated $84.5M.
  • Baker Bros. Advisors's ten largest holdings make up 74% of its $8.16B portfolio in Q2 2014.
  • Baker Bros. Advisors opened 7 new positions and closed 9 in Q2 2014.
  • Baker Bros. Advisors's portfolio value rose 3.8% quarter-over-quarter to $8.16B.

Based on Baker Bros. Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.